Unknown

Dataset Information

0

Treatment of extensively-drug resistant (XDR) Acinetobacter and impact on clinical outcomes in U.S. veterans affairs (VA) medical centers.


ABSTRACT:

Background

Guidelines for treatment of resistant Acinetobacter baumannii (AB) are limited, leaving a knowledge gap in best practices for treatment. This study described treatments and outcomes of extensively-drug resistant (XDR) AB.

Methods

Retrospective cohort study including patients with XDRAB (non-susceptible to at least 1 agent in all but 2 or fewer classes) and antibiotic treatment between 2012 and 2018 at Veterans Affairs Medical Centers. Descriptive statistics summarized antibiotics; propensity score adjusted regression models were fit to compare outcomes.

Results

Two hundred and seventy-six patients with 439 XDRAB cultures and Gram-negative targeted antibiotic treatment were included. One hundred and eighteen (43%) patients received monotherapy while 158 (57%) received combination therapy, most commonly including a carbapenem (n = 106, 67%) and polymyxin (n = 66, 42%). One hundred and eighty-four (67%) patients received inadequate treatment. In adjusted models, combination therapy did not decrease the odds of in-hospital (aOR 1.24, 95%CI 0.60-2.59) or 30-day (aOR 1.43, 95%CI 0.86-2.38) mortality, or median postculture length of stay (aIRR 1.11, 95%CI 0.86-1.43). Likewise, receipt of inadequate treatment was not associated with poorer outcomes.

Conclusions

In this national cohort of patients with XDRAB, neither combination therapy nor receipt of adequate treatment improved outcomes. Further research is needed on optimal management of this difficult-to-treat pathogen with few effective antibiotic options.

SUBMITTER: Fitzpatrick MA 

PROVIDER: S-EPMC9338173 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Treatment of extensively-drug resistant (XDR) Acinetobacter and impact on clinical outcomes in U.S. veterans affairs (VA) medical centers.

Fitzpatrick Margaret A MA   Suda Katie J KJ   Poggensee Linda L   Vivo Amanda A   Wilson Geneva G   Jones Makoto M MM   Evans Martin M   Safdar Nasia N   Evans Charlesnika T CT  

American journal of infection control 20220130 9


<h4>Background</h4>Guidelines for treatment of resistant Acinetobacter baumannii (AB) are limited, leaving a knowledge gap in best practices for treatment. This study described treatments and outcomes of extensively-drug resistant (XDR) AB.<h4>Methods</h4>Retrospective cohort study including patients with XDRAB (non-susceptible to at least 1 agent in all but 2 or fewer classes) and antibiotic treatment between 2012 and 2018 at Veterans Affairs Medical Centers. Descriptive statistics summarized a  ...[more]

Similar Datasets

| S-EPMC11544761 | biostudies-literature
| S-EPMC9002339 | biostudies-literature
| S-EPMC8505267 | biostudies-literature
| S-EPMC9311468 | biostudies-literature
| S-EPMC7449414 | biostudies-literature
| S-EPMC10339365 | biostudies-literature
| S-EPMC8243642 | biostudies-literature
| S-EPMC9223204 | biostudies-literature
| S-EPMC3528970 | biostudies-other
| S-EPMC8917078 | biostudies-literature